This new proposal has the potential to increase the number of positive appraisals from NICE, but only if companies offer the very best price to the NHS. What does this mean for NICE’s existing ‘end of life criteria’ or its quality adjusted life years (QALYs) measure? Find out more here. (Source: Matthew Dennis, FirstWord Pharma, 3/27/14).
You are here: / / NICE Opens Consultation On New Value-Based Assessment Scheme